A subpopulation of B220(+) cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors

被引:192
作者
Rolink, A
tenBoekel, E
Melchers, F
Fearon, DT
Krop, I
Andersson, J
机构
[1] BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND
[2] UPPSALA UNIV, BMC, DEPT IMMUNOL, UPPSALA, SWEDEN
[3] UNIV CAMBRIDGE, SCH CLIN MED, WELLCOME TRUST IMMUNOL UNIT, CAMBRIDGE CB2 2SP, ENGLAND
[4] JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21218 USA
基金
英国惠康基金;
关键词
D O I
10.1084/jem.183.1.187
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Bone marrow of both normal and rearrangement-deficient mice contains a small population of B220(CD45R)(+) cells, which do not express the B lineage marker CD19. Instead, part of this population coexpresses the surface marker CD43 and lacks or expresses very low levels of heat stable antigen (HSA) and BP-1, thus representing a pan: or Hardy's fraction A (B220(+)- CD43(+)HSA(-), BP-1(-)) of B lineage development. However, some 20-40% of these B220(+)- CD19(-) cells also coexpress the NK1.1 surface molecule and do not express genes Like V-preB or B29 restricted to the B cell lineage. These cells respond to recombinant interleukin 2 in vitro, and develop into killer cells that can lyse the prototypic NK target tumor cell, YAC-1, as well as syngeneic normal lipopolysaccharide or concanavalin A blasts, providing they lack the surface expression of major histocompatibility complex class I molecules. The implications of these findings for studies on B lymphopoiesis are discussed. It is suggested that the CD19-specific monoclonal antibody is more reliable, as in humans, than B220(CD45R) to detect B Lineage cells in mice.
引用
收藏
页码:187 / 194
页数:8
相关论文
共 43 条